Regeneron Pharmaceuticals Inc.

10/22/2021 | Press release | Distributed by Public on 10/21/2021 23:03

Dupixent® (dupilumab) is the First Biologic to Significantly Reduce Itch and Skin Lesions in Phase 3 Trial for Prurigo Nodularis, Demonstrating the Role of Type 2 Inflammation[...]